Novocure Stock Plunges On Likelihood For Diminishing Sales Growth In 2021

Novocure Stock Plunges On Likelihood For Diminishing Sales Growth In 2021

Novocure's streak of bullish revenue growth is expected to diminish, an analyst said Thursday as NVCR stock tumbled on several delayed clinical studies. Earnings also came in light.